{"preliminary_commentary":{"by_channel":{"youtube":13,"x_thread":4,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05006716\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["tacabrutideg (BGB-16673)"]],"indication":"B-cell malignancies","name":"CaDAnCe-101","nct_id":"NCT05006716","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cadance-101-nct05006716. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CaDAnCe-101","arms":[{"description":"Dose escalation in specific subtypes of non-Hodgkin lymphoma (NHL), including relapsed or refractory (R/R) marginal zone lymphoma (MZL), R/R follicular lymphoma (FL) Grades 1, 2, and 3a, R/R mantle cell lymphoma (MCL), R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), R/R diffuse large B-cell lymphoma (DLBCL), R/R Richter's transformation (RT), and R/R Waldenström macroglobulinemia (WM), to evaluate the safety and tolerability of tacabrutideg.","label":"Part 1a (Monotherapy Dose Escalation)","type":"EXPERIMENTAL"},{"description":"Participants with R/R MZL, MCL, CLL/SLL, and WM will be enrolled at selected doses to help determine the recommended dose(s) for expansion (RDFE(s)) for tacabrutideg.","label":"Part 1b (Monotherapy Safety Expansion)","type":"EXPERIMENTAL"},{"description":"Additional safety data will be collected from participants with R/R MZL, WM, RT, DLBCL, or FL to confirm the RDFE(s) of tacabrutideg for those with non-CLL/SLL/MCL histologies.","label":"Part 1c (Additional Monotherapy Safety Expansion)","type":"EXPERIMENTAL"},{"description":"Participants with R/R CLL/SLL will be enrolled at selected RDFE(s) to generate additional safety and efficacy data for tacabrutideg.","label":"Part 1d (Additional Monotherapy Safety Expansion in R/R CLL/SLL)","type":"EXPERIMENTAL"},{"description":"Japanese participants with R/R MZL, FL, MCL, CLL/SLL, and WM will be enrolled at selected RDFE(s) to assess the safety and tolerability of tacabrutideg.","label":"Part 1e (Japan-only Cohort)","type":"EXPERIMENTAL"},{"description":"Participants with CLL/SLL, MCL, WM, MZL, or Richter's transformation to DLBCL who have not received a prior BTKi (either covalent or noncovalent) will be enrolled at selected dose levels.","label":"Part 1f (Additional Monotherapy Safety Expansion in BTKi Naive B-Cell Malignancies)","type":"EXPERIMENTAL"},{"description":"Cohorts of participants with R/R CLL/SLL, R/R MCL, R/R WM, R/R MZL, R/R FL, R/R RT, and R/R DLBCL will be enrolled to receive the RDFE(s) identified in Phase 1 to further evaluate the safety and efficacy of tacabrutideg.","label":"Phase 2 (Monotherapy Expansion)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-03","type":"ESTIMATED"},"conditions":["B-cell Malignancy","Marginal Zone Lymphoma","Follicular Lymphoma","Non-Hodgkin Lymphoma","Waldenström Macroglobulinemia","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Mantle Cell Lymphoma","Diffuse Large B Cell Lymphoma","Richter Transformation"],"enrollment":{"count":689,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Tacabrutideg","otherNames":["BGB-16673"],"type":"DRUG"}],"last_update":"2026-10-05","lead_sponsor":"BeOne Medicines","official_title":"A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-03","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 1: Number of Participants with Adverse Events (AEs)","timeFrame":"From the first dose of tacabrutideg until 30 days after the last dose of the study drug or before the initiation of a new anticancer therapy, whichever occurs first (Up to 47 weeks)"},{"measure":"Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Tacabrutideg","timeFrame":"Approximately 28 days"},{"measure":"Phase 1: Recommended dose(s) for Expansion (RDFE) of tacabrutideg","timeFrame":"Approximately 3 years"},{"measure":"Phase 2: Overall response rate (ORR)","timeFrame":"approximately 3 years"}],"references":[],"start_date":{"date":"2021-09-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies","url":"https://clinicaltrials.gov/study/NCT05006716"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cadance-101-nct05006716"}